Volume: 61 - Issue: 1
First page: 85 - Last page: 89
P.W. Hellings - W.J. Fokkens - R. Orlandi - G.F. Adriaensen - I. Alobid - F.M. Baroody - L. Bjermer - B.A. Senior - A. Cervin - N.A. Cohen - J. Constantinidis - E. De Corso - M. Desrosiers - Z. Diamant - R.G. Douglas - S. Gane - P. Gevaert - J.K. Han - R.J. Harvey - C. Hopkins - R.C. Kern - B.N. Landis - J.T. Lee - S.E. Lee - A. Leunig - V.J. Lund - M. Bernal-Sprekelsen - J. Mullol - C. Philpott - E. Prokopakis - S. Reitsma - D. Ryan - S. Salmi - G. Scadding - R.J. Schlosser - A. Steinsvik - P.V. Tomazic - E. Van Staeyen - T. Van Zele - O. Vanderveken - A-S. Viskens - D. Conti - M. Wagenmann
DOI: 10.4193/Rhin22.344
Chronic rhinosinusitis (CRS) is known to affect around 5 % of
the total population, with major impact on the quality of life of
those severely affected (1). Despite a substantial burden on individuals,
society and health economies, CRS often remains underdiagnosed,
under-estimated and under-treated (2). International
guidelines like the European Position Paper on Rhinosinusitis
and Nasal Polyps (EPOS) (3) and the International Consensus
statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR)
(4) offer physicians insight into the recommended treatment
options for CRS, with an overview of effective strategies and
guidance of diagnosis and care throughout the disease journey
of CRS.
Rhinology 61-1: 85-89, 2023
To see the issue content and the abstract you do not have to login
Please login to download the full articles
If you do not have a subscription to Rhinology please consider taking one.